The research is taking place under the umbrella of DOE’s newly established National Virtual Biotechnology Laboratory, a consortium of DOE national laboratories with core capabilities relevant to the threats posed by COVID-19.
The testing research working group involves eight DOE national labs and is funded for the next six months.
The working group identified several opportunities where additional R&D can improve existing COVID-19 diagnostic methods or help develop new capabilities for current and evolving pandemic needs. The opportunities capitalize on national lab strengths and expertise, and will help the nation prepare to scale up testing in the future when needed.
The eight national labs formed five teams to take on different facets of the R&D work. Berkeley Lab scientists lead three of the teams, and contribute to a fourth.
Rebecca Abergel, a faculty scientist in the Chemical Sciences Division, is leading a team to help establish validated alternatives to the instruments and reagents used for the currently approved diagnostics. This effort will provide normalized protocols to the broader community.
A patterned surface of microelectrodes used to control the position, rate and mixing of droplets on the microfluidic device. (Jess Sustarich, Sandia National Laboratories, Livermore, CA.)
The R&D work at Berkeley Lab will be conducted within the constraints imposed by the current "safe and stable standby" status of the Lab, which includes minimal on-site staffing to help ensure the health and safety of Lab staff and the community.
The research is among a wide range of COVID-19 related research projects underway at Berkeley Lab, which has capabilities and facilities that are being called into action to quickly assist in the national COVID-19 response.